Global DNA Methylation Market: Focus on Products, Technologies, Applications, End Users, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Market Report Coverage - DNA Methylation
Market Segmentation
Abcam plc, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., Merck Group, Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Active Motif, Inc., Diagenode Diagnostics SA, EpiGentek Group Inc., New England Biolabs, Inc., and Zymo Research Corporation.
Key Questions Answered in this Report:
DNA methylation is a heritable epigenetic marker which involves the covalent transfer of a methyl group to the C-5 position of the cytosine ring of DNA by enzymes known as DNA methyltransferases (DNMTs). In humans, DNA methylation occurs primarily at cytosines in any context of the genome. More than 98% of DNA methylation occurs in a CpG dinucleotide context in somatic cells. The current DNA methylation market is mainly dominated by several diagnostic majors, such as Exact Sciences Corporation, Illumina, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc., which offer a wide variety of diagnostics and research-based products for detection of DNA methylation in genomes.
These products are generally based on technologies, such as polymerase chain reaction (PCR), microarrays, and sequencing, including both traditional and next-generation sequencing. The underlying utility of diagnostic testing for DNA methylation is based on the identification of clinically actionable genetic function, which provide crucial information on diagnosis, prognosis, and theranostics of genetic disorders and thereby facilitates clinical work-up, treatment management, and therapeutic selection.
The existing market of DNA methylation is favored by multiple factors, which include a global increase in cancer prevalence and declining costs and increasing output of sequencing. In addition, an increasing number of product approvals and launches pertaining to the global DNA methylation market will provide a lucrative growth for this market. Moreover, increasing use of early-stage biomarkers in cancer profiling is the key driving factor for the market.
Government funding is also one of the major growth factors for the DNA methylation market, because increasing funding by the government is expected to facilitate research institutes and key players to develop, as well as market novel assays useful for the diagnosis of several tumors. Increasing funding will lead to liquidity of the cancer profiling market, and thus, companies will develop various testing options to identify the underlying mutations that serve as a possible cause for the disease. All these factors are, therefore, expected to contribute to the market growth during the forecast period.
Within the research report, the market is segmented on the basis of product type, technology, application, end user, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-degree coverage of the domain.
Competitive Landscape
On the basis of region, North America is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe. This is a result of the presence of leading industry players in this region, coupled up with the highest prevalence of cancer in 2018.
Major players, including Illumina, Inc., MDxHealth S.A., Diagenode Diagnostics S.A., and Thermo Fisher Scientific Inc., among others, led the number of key developments witnessed by the market during the period 2017-2020. The market was dominated by players such as Exact Sciences Corporation, Illumina, Inc., and QIAGEN N.V. in 2018 and 2019. These companies ensured their market stature through several key developments undertaken during the period.
Market Report Coverage - DNA Methylation
Market Segmentation
- By Product: Consumables, Instruments, and Software
- By Technology: Polymerase Chain Reaction (PCR), Sequencing, Microarray, and others.
- By Application: Clinical and Translational Research Segments
- By End User: Pharmaceutical and Biotechnology Companies, Research and Academic Institutions, Contract Research Organizations (CROs), and others.
- By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World
- North America: U.S. and Canada
- Europe: Germany, U.K., France, Italy, Spain, and Rest-of-Europe
- Asia-Pacific: China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific
- Latin America: Brazil, Mexico, and Rest-of-Latin America
- Rest-of-the-World
- Global Increase in Cancer Prevalence
- Increasing Government Funding for Healthcare
- Declining Costs and Increasing Output of Sequencing
- High Cost of Instrument
- Lack of High-Complexity Testing Centers and Skilled Professionals in High-Growth Regions
- Low Adoption in Diagnostic Applications
- Growing Trend of Methylome Sequencing for Precision Medicine
- Advancing Technological Developments for Methylome Sequencing
- Growth in Non-Oncology Applications of DNA Methylation
Abcam plc, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., Merck Group, Pacific Biosciences of California, Inc., PerkinElmer, Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Active Motif, Inc., Diagenode Diagnostics SA, EpiGentek Group Inc., New England Biolabs, Inc., and Zymo Research Corporation.
Key Questions Answered in this Report:
- What are the major market drivers, challenges, and opportunities in, and their respective impacts on the global DNA methylation market?
- What are the key development strategies which are implemented by the major players in order to sustain in the competitive market?
- Which is the dominant product type developed by the leading and emerging players for the global DNA methylation market?
- What are the key technologies that have been used by leading players in the global DNA methylation market?
- How each segment of the market is expected to grow during the forecast period from 2020 to 2030 based on:
- product type
- technology
- application
- end user
- region
- Which companies are anticipated to be highly disruptive in the future, and why?
- What are the key application areas for DNA methylation in 2020, and which application areas are expected to witness growth in the forecast period?
DNA methylation is a heritable epigenetic marker which involves the covalent transfer of a methyl group to the C-5 position of the cytosine ring of DNA by enzymes known as DNA methyltransferases (DNMTs). In humans, DNA methylation occurs primarily at cytosines in any context of the genome. More than 98% of DNA methylation occurs in a CpG dinucleotide context in somatic cells. The current DNA methylation market is mainly dominated by several diagnostic majors, such as Exact Sciences Corporation, Illumina, Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc., which offer a wide variety of diagnostics and research-based products for detection of DNA methylation in genomes.
These products are generally based on technologies, such as polymerase chain reaction (PCR), microarrays, and sequencing, including both traditional and next-generation sequencing. The underlying utility of diagnostic testing for DNA methylation is based on the identification of clinically actionable genetic function, which provide crucial information on diagnosis, prognosis, and theranostics of genetic disorders and thereby facilitates clinical work-up, treatment management, and therapeutic selection.
The existing market of DNA methylation is favored by multiple factors, which include a global increase in cancer prevalence and declining costs and increasing output of sequencing. In addition, an increasing number of product approvals and launches pertaining to the global DNA methylation market will provide a lucrative growth for this market. Moreover, increasing use of early-stage biomarkers in cancer profiling is the key driving factor for the market.
Government funding is also one of the major growth factors for the DNA methylation market, because increasing funding by the government is expected to facilitate research institutes and key players to develop, as well as market novel assays useful for the diagnosis of several tumors. Increasing funding will lead to liquidity of the cancer profiling market, and thus, companies will develop various testing options to identify the underlying mutations that serve as a possible cause for the disease. All these factors are, therefore, expected to contribute to the market growth during the forecast period.
Within the research report, the market is segmented on the basis of product type, technology, application, end user, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-degree coverage of the domain.
Competitive Landscape
On the basis of region, North America is expected to retain a leading position throughout the forecast period 2020-2030, followed by Europe. This is a result of the presence of leading industry players in this region, coupled up with the highest prevalence of cancer in 2018.
Major players, including Illumina, Inc., MDxHealth S.A., Diagenode Diagnostics S.A., and Thermo Fisher Scientific Inc., among others, led the number of key developments witnessed by the market during the period 2017-2020. The market was dominated by players such as Exact Sciences Corporation, Illumina, Inc., and QIAGEN N.V. in 2018 and 2019. These companies ensured their market stature through several key developments undertaken during the period.
EXECUTIVE SUMMARY
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global DNA Methylation Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Market Definition
4.2 DNA Methylation: Impact on Human Health
4.3 Market Size and Growth Potential, $Million, 2019-2030
4.4 Future Potential
4.5 COVID-19 Impact on the Global DNA Methylation Market
5 GLOBAL DNA METHYLATION MARKET: INDUSTRY ANALYSIS
5.1 Overview
5.2 Legal Requirements and Framework in the U.S.
5.3 Legal Requirements and Framework in Europe
5.4 Legal Requirements and Framework in Asia-Pacific
5.4.1 China
5.4.2 Japan
6 GLOBAL DNA METHYLATION MARKET: MARKET DYNAMICS
6.1 Overview
6.2 Iceberg Analysis
6.3 Impact Analysis
6.4 Market Drivers
6.4.1 Global Increase in Cancer Prevalence
6.4.2 Increasing Government Funding for Healthcare
6.4.3 Declining Costs and Increasing Output of Sequencing
6.5 Market Restraints
6.5.1 High Cost of Instrument
6.5.2 Lack of High-Complexity Testing Centers and Skilled Professionals in High-Growth Regions
6.5.3 Low Adoption in Diagnostic Applications
6.6 Market Opportunities
6.6.1 Growing Trend of Methylome Sequencing for Precision Medicine
6.6.2 Advancing Technological Developments for Methylome Sequencing
6.6.3 Growth in Non-Oncology Applications of DNA Methylation
7 COMPETITIVE LANDSCAPE
7.1 Product Launches and Upgrades
7.2 Synergistic Activities
7.3 Acquisitions
7.4 Product Approvals, Business Expansion, and Other Activities
7.5 Market Share Analysis, 2018-2019
7.6 Growth Share Analysis
7.6.1 Growth Share Analysis (by Company)
7.6.2 Growth Share Analysis (by Technology)
7.6.3 Growth Share Analysis (by Application)
8 GLOBAL DNA METHYLATION MARKET (BY PRODUCT TYPE)
8.1 Overview
8.2 Consumables
8.3 Instruments
8.4 Software
9 GLOBAL DNA METHYLATION MARKET (BY TECHNOLOGY)
9.1 Overview
9.2 Polymerase Chain Reaction (PCR)
9.3 Sequencing
9.3.1 Next-Generation Sequencing (NGS)
9.3.2 Traditional Sequencing
9.4 Microarray
9.5 Other Technologies
10 GLOBAL DNA METHYLATION MARKET (BY APPLICATION)
10.1 Overview
10.2 Clinical Applications
10.3 Translational Research
10.3.1 Oncology Research
10.3.2 Non-Oncology Research
10.3.3 Other Research Applications
11 GLOBAL DNA METHYLATION MARKET (BY END USER)
11.1 Overview
11.2 Pharmaceutical and Biotechnology Companies
11.3 Research and Academic Institutions
11.4 Contract Research Organizations
11.5 Other End Users
12 GLOBAL DNA METHYLATION MARKET (BY REGION)
12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.2.3 North America DNA Methylation Market (by Translational Research), 2019-2030
12.3 Europe
12.3.1 Germany
12.3.2 U.K.
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 Rest-of-Europe
12.3.7 Europe DNA Methylation Market (by Translational Research), 2019-2030
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Australia
12.4.6 Rest-of-APAC
12.4.7 Asia-Pacific DNA Methylation Market (by Translational Research), 2019-2030
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest-of-Latin America
12.5.4 Latin America DNA Methylation Market (by Translational Research), 2019-2030
12.6 Rest-of-the-World
13 COMPANY PROFILES
13.1 Overview
13.2 Abcam plc
13.2.1 Company Overview
13.2.2 Role of Abcam plc in the Global DNA Methylation Market
13.2.3 Financials
13.2.4 Key Insights About Financial Health of the Company
13.2.5 SWOT Analysis
13.3 Active Motif, Inc.
13.3.1 Company Overview
13.3.2 Role of Active Motif, Inc. in the Global DNA Methylation Market
13.3.3 SWOT Analysis
13.4 Agilent Technologies, Inc.
13.4.1 Company Overview
13.4.2 Role of Agilent Technologies, Inc. in the Global DNA Methylation Market
13.4.3 Financials
13.4.4 Key Insights About Financial Health of the Company
13.4.5 SWOT Analysis
13.5 Bio-Rad Laboratories, Inc.
13.5.1 Company Overview
13.5.2 Role of Bio-Rad Laboratories, Inc. in the Global DNA Methylation Market
13.5.3 Financials
13.5.4 Key Insights About Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Diagenode Diagnostics S.A.
13.6.1 Company Overview
13.6.2 Role of Diagenode Diagnostics S.A. in the Global DNA Methylation Market
13.6.3 SWOT Analysis
13.7 EpiGentek Group Inc.
13.7.1 Company Overview
13.7.2 Role of EpiGentek Group Inc. in the Global DNA Methylation Market
13.7.3 SWOT Analysis
13.8 Exact Sciences Corporation
13.8.1 Company Overview
13.8.2 Role of Exact Sciences Corporation in the Global DNA Methylation Market
13.8.3 Financials
13.8.4 Key Insights About Financial Health of the Company
13.8.5 SWOT Analysis
13.9 F. Hoffmann-La Roche Ltd.
13.9.1 Company Overview
13.9.2 Role of F. Hoffmann-La Roche Ltd in the Global DNA Methylation Market
13.9.3 Financials
13.9.4 Key Insights About Financial Health of the Company
13.9.5 SWOT Analysis
13.1 Illumina, Inc.
13.10.1 Company Overview
13.10.2 Role of Illumina, Inc. in the Global DNA Methylation Market
13.10.3 Financials
13.10.4 Key Insights About Financial Health of the Company
13.10.5 SWOT Analysis
13.11 Merck KGaA
13.11.1 Company Overview
13.11.2 Role of Merck KGaA in the Global DNA Methylation Market
13.11.3 Financials
13.11.4 Key Insights About Financial Health of the Company
13.11.5 SWOT Analysis
13.12 New England Biolabs, Inc.
13.12.1 Company Overview
13.12.2 Role of New England Biolabs, Inc. in the Global DNA Methylation Market
13.12.3 SWOT Analysis
13.13 Pacific Biosciences of California, Inc.
13.13.1 Company Overview
13.13.2 Role of Pacific Biosciences of California, Inc. in the Global DNA Methylation Market
13.13.3 Financials
13.13.4 Key Insights About Financial Health of the Company
13.13.5 SWOT Analysis
13.14 PerkinElmer, Inc.
13.14.1 Company Overview
13.14.2 Role of PerkinElmer, Inc. in the Global DNA Methylation Market
13.14.3 Financials
13.14.4 Key Insights About Financial Health of the Company
13.14.5 SWOT Analysis
13.15 QIAGEN N.V.*
13.15.1 Company Overview
13.15.2 Role of QIAGEN N.V. in the Global DNA Methylation Market
13.15.3 Financials
13.15.4 Key Insights About Financial Health of the Company
13.15.5 SWOT Analysis
13.16 Thermo Fisher Scientific Inc.
13.16.1 Company Overview
13.16.2 Role of Thermo Fisher Scientific Inc. in the Global DNA Methylation Market
13.16.3 Financials
13.16.4 Key Insights About Financial Health of the Company
13.16.5 SWOT Analysis
13.17 Zymo Research Corporation
13.17.1 Company Overview
13.17.2 Role of Zymo Research Corporation in the Global DNA Methylation Market
13.17.3 SWOT Analysis
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global DNA Methylation Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Market Definition
4.2 DNA Methylation: Impact on Human Health
4.3 Market Size and Growth Potential, $Million, 2019-2030
4.4 Future Potential
4.5 COVID-19 Impact on the Global DNA Methylation Market
5 GLOBAL DNA METHYLATION MARKET: INDUSTRY ANALYSIS
5.1 Overview
5.2 Legal Requirements and Framework in the U.S.
5.3 Legal Requirements and Framework in Europe
5.4 Legal Requirements and Framework in Asia-Pacific
5.4.1 China
5.4.2 Japan
6 GLOBAL DNA METHYLATION MARKET: MARKET DYNAMICS
6.1 Overview
6.2 Iceberg Analysis
6.3 Impact Analysis
6.4 Market Drivers
6.4.1 Global Increase in Cancer Prevalence
6.4.2 Increasing Government Funding for Healthcare
6.4.3 Declining Costs and Increasing Output of Sequencing
6.5 Market Restraints
6.5.1 High Cost of Instrument
6.5.2 Lack of High-Complexity Testing Centers and Skilled Professionals in High-Growth Regions
6.5.3 Low Adoption in Diagnostic Applications
6.6 Market Opportunities
6.6.1 Growing Trend of Methylome Sequencing for Precision Medicine
6.6.2 Advancing Technological Developments for Methylome Sequencing
6.6.3 Growth in Non-Oncology Applications of DNA Methylation
7 COMPETITIVE LANDSCAPE
7.1 Product Launches and Upgrades
7.2 Synergistic Activities
7.3 Acquisitions
7.4 Product Approvals, Business Expansion, and Other Activities
7.5 Market Share Analysis, 2018-2019
7.6 Growth Share Analysis
7.6.1 Growth Share Analysis (by Company)
7.6.2 Growth Share Analysis (by Technology)
7.6.3 Growth Share Analysis (by Application)
8 GLOBAL DNA METHYLATION MARKET (BY PRODUCT TYPE)
8.1 Overview
8.2 Consumables
8.3 Instruments
8.4 Software
9 GLOBAL DNA METHYLATION MARKET (BY TECHNOLOGY)
9.1 Overview
9.2 Polymerase Chain Reaction (PCR)
9.3 Sequencing
9.3.1 Next-Generation Sequencing (NGS)
9.3.2 Traditional Sequencing
9.4 Microarray
9.5 Other Technologies
10 GLOBAL DNA METHYLATION MARKET (BY APPLICATION)
10.1 Overview
10.2 Clinical Applications
10.3 Translational Research
10.3.1 Oncology Research
10.3.2 Non-Oncology Research
10.3.3 Other Research Applications
11 GLOBAL DNA METHYLATION MARKET (BY END USER)
11.1 Overview
11.2 Pharmaceutical and Biotechnology Companies
11.3 Research and Academic Institutions
11.4 Contract Research Organizations
11.5 Other End Users
12 GLOBAL DNA METHYLATION MARKET (BY REGION)
12.1 Overview
12.2 North America
12.2.1 U.S.
12.2.2 Canada
12.2.3 North America DNA Methylation Market (by Translational Research), 2019-2030
12.3 Europe
12.3.1 Germany
12.3.2 U.K.
12.3.3 France
12.3.4 Italy
12.3.5 Spain
12.3.6 Rest-of-Europe
12.3.7 Europe DNA Methylation Market (by Translational Research), 2019-2030
12.4 Asia-Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 South Korea
12.4.5 Australia
12.4.6 Rest-of-APAC
12.4.7 Asia-Pacific DNA Methylation Market (by Translational Research), 2019-2030
12.5 Latin America
12.5.1 Brazil
12.5.2 Mexico
12.5.3 Rest-of-Latin America
12.5.4 Latin America DNA Methylation Market (by Translational Research), 2019-2030
12.6 Rest-of-the-World
13 COMPANY PROFILES
13.1 Overview
13.2 Abcam plc
13.2.1 Company Overview
13.2.2 Role of Abcam plc in the Global DNA Methylation Market
13.2.3 Financials
13.2.4 Key Insights About Financial Health of the Company
13.2.5 SWOT Analysis
13.3 Active Motif, Inc.
13.3.1 Company Overview
13.3.2 Role of Active Motif, Inc. in the Global DNA Methylation Market
13.3.3 SWOT Analysis
13.4 Agilent Technologies, Inc.
13.4.1 Company Overview
13.4.2 Role of Agilent Technologies, Inc. in the Global DNA Methylation Market
13.4.3 Financials
13.4.4 Key Insights About Financial Health of the Company
13.4.5 SWOT Analysis
13.5 Bio-Rad Laboratories, Inc.
13.5.1 Company Overview
13.5.2 Role of Bio-Rad Laboratories, Inc. in the Global DNA Methylation Market
13.5.3 Financials
13.5.4 Key Insights About Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Diagenode Diagnostics S.A.
13.6.1 Company Overview
13.6.2 Role of Diagenode Diagnostics S.A. in the Global DNA Methylation Market
13.6.3 SWOT Analysis
13.7 EpiGentek Group Inc.
13.7.1 Company Overview
13.7.2 Role of EpiGentek Group Inc. in the Global DNA Methylation Market
13.7.3 SWOT Analysis
13.8 Exact Sciences Corporation
13.8.1 Company Overview
13.8.2 Role of Exact Sciences Corporation in the Global DNA Methylation Market
13.8.3 Financials
13.8.4 Key Insights About Financial Health of the Company
13.8.5 SWOT Analysis
13.9 F. Hoffmann-La Roche Ltd.
13.9.1 Company Overview
13.9.2 Role of F. Hoffmann-La Roche Ltd in the Global DNA Methylation Market
13.9.3 Financials
13.9.4 Key Insights About Financial Health of the Company
13.9.5 SWOT Analysis
13.1 Illumina, Inc.
13.10.1 Company Overview
13.10.2 Role of Illumina, Inc. in the Global DNA Methylation Market
13.10.3 Financials
13.10.4 Key Insights About Financial Health of the Company
13.10.5 SWOT Analysis
13.11 Merck KGaA
13.11.1 Company Overview
13.11.2 Role of Merck KGaA in the Global DNA Methylation Market
13.11.3 Financials
13.11.4 Key Insights About Financial Health of the Company
13.11.5 SWOT Analysis
13.12 New England Biolabs, Inc.
13.12.1 Company Overview
13.12.2 Role of New England Biolabs, Inc. in the Global DNA Methylation Market
13.12.3 SWOT Analysis
13.13 Pacific Biosciences of California, Inc.
13.13.1 Company Overview
13.13.2 Role of Pacific Biosciences of California, Inc. in the Global DNA Methylation Market
13.13.3 Financials
13.13.4 Key Insights About Financial Health of the Company
13.13.5 SWOT Analysis
13.14 PerkinElmer, Inc.
13.14.1 Company Overview
13.14.2 Role of PerkinElmer, Inc. in the Global DNA Methylation Market
13.14.3 Financials
13.14.4 Key Insights About Financial Health of the Company
13.14.5 SWOT Analysis
13.15 QIAGEN N.V.*
13.15.1 Company Overview
13.15.2 Role of QIAGEN N.V. in the Global DNA Methylation Market
13.15.3 Financials
13.15.4 Key Insights About Financial Health of the Company
13.15.5 SWOT Analysis
13.16 Thermo Fisher Scientific Inc.
13.16.1 Company Overview
13.16.2 Role of Thermo Fisher Scientific Inc. in the Global DNA Methylation Market
13.16.3 Financials
13.16.4 Key Insights About Financial Health of the Company
13.16.5 SWOT Analysis
13.17 Zymo Research Corporation
13.17.1 Company Overview
13.17.2 Role of Zymo Research Corporation in the Global DNA Methylation Market
13.17.3 SWOT Analysis
LIST OF TABLES
Table 5.1: Classification Rules of IVDs Under the IVDR
Table 5.2: Registration Criteria for IVD Medical Devices as per the NMPA
Table 8.1: Examples of Consumables in the Global DNA Methylation Market
Table 8.2: Examples of Instruments in Global DNA Methylation Market
Table 8.3: Examples of Software in the Global DNA Methylation Market
Table 5.1: Classification Rules of IVDs Under the IVDR
Table 5.2: Registration Criteria for IVD Medical Devices as per the NMPA
Table 8.1: Examples of Consumables in the Global DNA Methylation Market
Table 8.2: Examples of Instruments in Global DNA Methylation Market
Table 8.3: Examples of Software in the Global DNA Methylation Market
LIST OF FIGURES
Figure 1: Cancer Epigenetic Biomarker Publications Per Annum Vs. Cumulative Registered DNA Methylation-based In Vitro Diagnostics, 2010-2019
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global DNA Methylation Market
Figure 3: Global DNA Methylation Market (by Product), 2019 vs. 2030 ($Million)
Figure 4: Global DNA Methylation Market (by Technology), 2019 vs. 2030 ($Million)
Figure 5: Global DNA Methylation Market (by Application), 2019 vs. 2030 ($Million)
Figure 6: Global DNA Methylation Market (by End User), 2019 vs. 2030 ($Million)
Figure 7: Global DNA Methylation Market Snapshot
Figure 2.1: Global DNA Methylation Market Segmentation
Figure 3.1: Global DNA Methylation Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global DNA Methylation Market, 2019-2030
Figure 4.2: Global DNA Methylation Market: COVID-19 Impact
Figure 5.1: Components Considered for Clinical Evidence as per the IVDR
Figure 5.2: Medical Device Designation Process by MHLW and PMDA
Figure 6.1: Iceberg Analysis – Global DNA Methylation Market
Figure 6.2: Impact Analysis
Figure 6.3: Global Cancer Burden, 2018
Figure 6.4: Increasing Government Spending for Healthcare, 2017
Figure 6.5: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 6.6: Milestones for Clinical Implementation of a Candidate DNA Methylation Biomarker
Figure 6.7: Evolution of NGS-Based Techniques Applied to DNA Methylation Profiling
Figure 7.1: Share of Key Developments and Strategies, January 2017–May 2020
Figure 7.2: Product Launches Share (by Company), January 2017–May 2020
Figure 7.3: Synergistic Activities Share (by Company), January 2017–May 2020
Figure 7.4: Share of Acquisitions (by Company), January 2016–February 2020
Figure 7.5: Market Share Analysis for Global DNA Methylation Market, 2018 and 2019
Figure 7.6: Growth Share Analysis for Global DNA Methylation Market (by Company), 2019
Figure 7.7: Growth Share Analysis for Global DNA Methylation Market (by Technology), 2019-2030
Figure 7.8: Growth Share Analysis for Global DNA Methylation Sequencing Market (by Application), 2019-2030
Figure 8.1: Global DNA Methylation Market (by Product Type)
Figure 8.2: Global DNA Methylation Market (by Product Type), 2019 and 2030
Figure 8.3: Global DNA Methylation Market (by Consumable), 2019-2030
Figure 8.4: Global DNA Methylation Market (by Consumable), 2019 and 2030
Figure 8.5: Global DNA Methylation Market (Consumable, by Technology), 2019 and 2030
Figure 8.6: Global DNA Methylation Market (by Instruments), 2019-2030
Figure 8.7: Global DNA Methylation Market (Instrument, by Technology), 2019 and 2030
Figure 8.8: Global DNA Methylation Market (by Software), 2019-2030
Figure 9.1: Global DNA Methylation Market (by Technology)
Figure 9.2: Global DNA Methylation Market (by Technology), 2019-2030
Figure 9.3: Global DNA Methylation Market (by PCR), 2019-2030
Figure 9.4: Evolution of Sequencing for Molecular Diagnostics
Figure 9.5: Global DNA Methylation Market (by Sequencing), 2019 and 2030
Figure 9.6: Global DNA Methylation Market (by NGS), 2019-2030
Figure 9.7: Global DNA Methylation Market (by Traditional Sequencing), 2019-2030
Figure 9.8: Global DNA Methylation Market (by Microarray), 2019-2030
Figure 9.9: Global DNA Methylation Market (by Other Technologies), 2019-2030
Figure 10.1: Global DNA Methylation Market (by Application)
Figure 10.2: Global DNA Methylation Market (by Application), 2019-2030
Figure 10.3: Global DNA Methylation Market (by Clinical Applications), 2019-2030
Figure 10.4: Global DNA Methylation Market (by Translational Research), 2019 and 2030
Figure 10.5: Global DNA Methylation Market (by Oncology Research), 2019-2030
Figure 10.6: Global DNA Methylation Market (by Non-Oncology Research), 2019-2030
Figure 10.7: Global DNA Methylation Market (by Non-Oncology Research), 2019 and 2030
Figure 10.8: Global DNA Methylation Market (by Other Research Applications), 2019-2030
Figure 11.1: Global DNA Methylation Market (by End User)
Figure 11.2: Global DNA Methylation Market (by Pharmaceutical and Biotechnology Companies), 2019-2030
Figure 11.3: Global DNA Methylation Market (by Research and Academic Institutions), 2019-2030
Figure 11.4: Global DNA Methylation Market (by Contract Research Organizations), 2019-2030
Figure 11.5: Global DNA Methylation Market (by Other End Users), 2019-2030
Figure 12.1: Global DNA Methylation Market (by Region)
Figure 12.2: Global DNA Methylation Market (by Region), 2019-2030
Figure 12.3: North America DNA Methylation Market, 2019-2030
Figure 12.4: North America: Market Dynamics
Figure 12.5: North America DNA Methylation Market (by Country), 2019-2030
Figure 12.6: U.S. DNA Methylation Market, 2019-2030
Figure 12.7: Canada DNA Methylation Market, 2019-2030
Figure 12.8: North America DNA Methylation Market (by Translational Research), 2019-2030
Figure 12.9: Europe DNA Methylation Market, 2019-2030
Figure 12.10: Europe: Market Dynamics
Figure 12.11: Europe DNA Methylation Market (by Country), 2019-2030
Figure 12.12: Germany DNA Methylation Market, 2019-2030
Figure 12.13: U.K. DNA Methylation Market, 2019-2030
Figure 12.14: France DNA Methylation Market, 2019-2030
Figure 12.15: Italy DNA Methylation Market, 2019-2030
Figure 12.16: Spain DNA Methylation Market, 2019-2030
Figure 12.17: Rest-of-Europe DNA Methylation Market, 2019-2030
Figure 12.18: Europe DNA Methylation Market (by Translational Research), 2019-2030
Figure 12.19: Asia-Pacific DNA Methylation Market, 2019-2030
Figure 12.20: APAC: Market Dynamics
Figure 12.21: APAC DNA Methylation Market (by Country), 2019-2030
Figure 12.22: China DNA Methylation Market, 2019-2030
Figure 12.23: Japan DNA Methylation Market, 2019-2030
Figure 12.24: India DNA Methylation Market, 2019-2030
Figure 12.25: South Korea DNA Methylation Market, 2019-2030
Figure 12.26: Australia DNA Methylation Market, 2019-2030
Figure 12.27: RoAPAC DNA Methylation Market, 2019-2030
Figure 12.28: Asia-Pacific DNA Methylation Market (by Translational Research), 2019-2030
Figure 12.29: Latin America DNA Methylation Market, 2019-2030
Figure 12.30: Latin America: Market Dynamics
Figure 12.31: Latin America DNA Methylation Market (by Country), 2019-2030
Figure 12.32: Brazil DNA Methylation Market, 2019-2030
Figure 12.33: Mexico DNA Methylation Market, 2019-2030
Figure 12.34: Rest-of-Latin America DNA Methylation Market, 2019-2030
Figure 12.35: Latin America DNA Methylation Market (by Translational Research), 2019-2030
Figure 12.36: RoW DNA Methylation Market, 2019-2030
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Abcam plc: Product Portfolio
Figure 13.3: Abcam plc: Overall Financials, 2016-2018
Figure 13.4: Abcam plc: Revenue (by Region), 2016-2018
Figure 13.5: Abcam plc: R&D Expenditure, 2016-2018
Figure 13.6: Abcam plc: SWOT Analysis
Figure 13.7: Active Motif, Inc.: Product Portfolio
Figure 13.8: Active Motif, Inc.: SWOT Analysis
Figure 13.9: Agilent Technologies, Inc.: Product Portfolio
Figure 13.10: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 13.11: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 13.12: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 13.13: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 13.14: Agilent Technologies, Inc.: SWOT Analysis
Figure 13.15: Bio-Rad Laboratories, Inc.: Portfolio
Figure 13.16: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 13.17: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 13.18: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 13.19: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 13.20: Bio-Rad Laboratories
Figure 13.21: Diagenode Diagnostics S.A.: Product Portfolio
Figure 13.22: Diagenode Diagnostics S.A.: SWOT Analysis
Figure 13.23: EpiGentek Group Inc.: Product Portfolio
Figure 13.24: EpiGentek Group Inc.: SWOT Analysis
Figure 13.25: Exact Sciences Corporation: Portfolio
Figure 13.26: Exact Sciences Corporation: Overall Financials, 2017-2019
Figure 13.27: Exact Sciences Corporation: Revenue (by Segment), 2017-2019
Figure 13.28: Exact Sciences Corporation: Revenue (by Region), 2017-2019
Figure 13.29: Exact Sciences Corporation: R&D Expenditure, 2017-2019
Figure 13.30: Exact Sciences Corporation
Figure 13.33: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 13.34: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 13.35: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.36: F. Hoffmann-La Roche: SWOT Analysis
Figure 13.37: Illumina, Inc.: Product Portfolio
Figure 13.38: Illumina, Inc.: Overall Financials, 2017-2019
Figure 13.39: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 13.40: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 13.41: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 13.42: Illumina, Inc.: SWOT Analysis
Figure 13.43: Merck KGaA: Overall Product Portfolio
Figure 13.44: Merck KGaA: Overall Financials, 2017-2019
Figure 13.45: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 13.46: Merck KGaA: Revenue (by Region), 2017-2019
Figure 13.47: Merck KGaA: Life Science Segment Revenue (by Region), 2017-2019
Figure 13.48: Merck KGaA: R&D Expenditure, 2016-2018
Figure 13.49: Merck KGaA: SWOT Analysis
Figure 13.50: New England Biolabs, Inc.: Product Portfolio
Figure 13.51: New England Biolabs, Inc.: SWOT Analysis
Figure 13.52: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 13.53: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 13.54: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
Figure 13.55: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 13.56: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 13.57: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 13.58: PerkinElmer, Inc.: Portfolio
Figure 13.59: PerkinElmer, Inc.: Overall Financials, 2017-2019
Figure 13.60: PerkinElmer, Inc.: Revenue (by Segment), 2017-2019
Figure 13.61: PerkinElmer, Inc.: Revenue (by Region), 2017-2019
Figure 13.62: PerkinElmer, Inc.: R&D Expenditure, 2017-2019
Figure 13.63: PerkinElmer, Inc.: SWOT Analysis
Figure 13.64: QIAGEN N.V.: Portfolio
Figure 13.65: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 13.66: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 13.67: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 13.68: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 13.69: QIAGEN N.V.: SWOT Analysis
Figure 13.70: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 13.71: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 13.72: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 13.73: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 13.74: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 13.75: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 13.76: Zymo Research Corporation: Product Portfolio
Figure 13.77: Zymo Research Corporation: SWOT Analysis
Figure 1: Cancer Epigenetic Biomarker Publications Per Annum Vs. Cumulative Registered DNA Methylation-based In Vitro Diagnostics, 2010-2019
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global DNA Methylation Market
Figure 3: Global DNA Methylation Market (by Product), 2019 vs. 2030 ($Million)
Figure 4: Global DNA Methylation Market (by Technology), 2019 vs. 2030 ($Million)
Figure 5: Global DNA Methylation Market (by Application), 2019 vs. 2030 ($Million)
Figure 6: Global DNA Methylation Market (by End User), 2019 vs. 2030 ($Million)
Figure 7: Global DNA Methylation Market Snapshot
Figure 2.1: Global DNA Methylation Market Segmentation
Figure 3.1: Global DNA Methylation Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global DNA Methylation Market, 2019-2030
Figure 4.2: Global DNA Methylation Market: COVID-19 Impact
Figure 5.1: Components Considered for Clinical Evidence as per the IVDR
Figure 5.2: Medical Device Designation Process by MHLW and PMDA
Figure 6.1: Iceberg Analysis – Global DNA Methylation Market
Figure 6.2: Impact Analysis
Figure 6.3: Global Cancer Burden, 2018
Figure 6.4: Increasing Government Spending for Healthcare, 2017
Figure 6.5: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 6.6: Milestones for Clinical Implementation of a Candidate DNA Methylation Biomarker
Figure 6.7: Evolution of NGS-Based Techniques Applied to DNA Methylation Profiling
Figure 7.1: Share of Key Developments and Strategies, January 2017–May 2020
Figure 7.2: Product Launches Share (by Company), January 2017–May 2020
Figure 7.3: Synergistic Activities Share (by Company), January 2017–May 2020
Figure 7.4: Share of Acquisitions (by Company), January 2016–February 2020
Figure 7.5: Market Share Analysis for Global DNA Methylation Market, 2018 and 2019
Figure 7.6: Growth Share Analysis for Global DNA Methylation Market (by Company), 2019
Figure 7.7: Growth Share Analysis for Global DNA Methylation Market (by Technology), 2019-2030
Figure 7.8: Growth Share Analysis for Global DNA Methylation Sequencing Market (by Application), 2019-2030
Figure 8.1: Global DNA Methylation Market (by Product Type)
Figure 8.2: Global DNA Methylation Market (by Product Type), 2019 and 2030
Figure 8.3: Global DNA Methylation Market (by Consumable), 2019-2030
Figure 8.4: Global DNA Methylation Market (by Consumable), 2019 and 2030
Figure 8.5: Global DNA Methylation Market (Consumable, by Technology), 2019 and 2030
Figure 8.6: Global DNA Methylation Market (by Instruments), 2019-2030
Figure 8.7: Global DNA Methylation Market (Instrument, by Technology), 2019 and 2030
Figure 8.8: Global DNA Methylation Market (by Software), 2019-2030
Figure 9.1: Global DNA Methylation Market (by Technology)
Figure 9.2: Global DNA Methylation Market (by Technology), 2019-2030
Figure 9.3: Global DNA Methylation Market (by PCR), 2019-2030
Figure 9.4: Evolution of Sequencing for Molecular Diagnostics
Figure 9.5: Global DNA Methylation Market (by Sequencing), 2019 and 2030
Figure 9.6: Global DNA Methylation Market (by NGS), 2019-2030
Figure 9.7: Global DNA Methylation Market (by Traditional Sequencing), 2019-2030
Figure 9.8: Global DNA Methylation Market (by Microarray), 2019-2030
Figure 9.9: Global DNA Methylation Market (by Other Technologies), 2019-2030
Figure 10.1: Global DNA Methylation Market (by Application)
Figure 10.2: Global DNA Methylation Market (by Application), 2019-2030
Figure 10.3: Global DNA Methylation Market (by Clinical Applications), 2019-2030
Figure 10.4: Global DNA Methylation Market (by Translational Research), 2019 and 2030
Figure 10.5: Global DNA Methylation Market (by Oncology Research), 2019-2030
Figure 10.6: Global DNA Methylation Market (by Non-Oncology Research), 2019-2030
Figure 10.7: Global DNA Methylation Market (by Non-Oncology Research), 2019 and 2030
Figure 10.8: Global DNA Methylation Market (by Other Research Applications), 2019-2030
Figure 11.1: Global DNA Methylation Market (by End User)
Figure 11.2: Global DNA Methylation Market (by Pharmaceutical and Biotechnology Companies), 2019-2030
Figure 11.3: Global DNA Methylation Market (by Research and Academic Institutions), 2019-2030
Figure 11.4: Global DNA Methylation Market (by Contract Research Organizations), 2019-2030
Figure 11.5: Global DNA Methylation Market (by Other End Users), 2019-2030
Figure 12.1: Global DNA Methylation Market (by Region)
Figure 12.2: Global DNA Methylation Market (by Region), 2019-2030
Figure 12.3: North America DNA Methylation Market, 2019-2030
Figure 12.4: North America: Market Dynamics
Figure 12.5: North America DNA Methylation Market (by Country), 2019-2030
Figure 12.6: U.S. DNA Methylation Market, 2019-2030
Figure 12.7: Canada DNA Methylation Market, 2019-2030
Figure 12.8: North America DNA Methylation Market (by Translational Research), 2019-2030
Figure 12.9: Europe DNA Methylation Market, 2019-2030
Figure 12.10: Europe: Market Dynamics
Figure 12.11: Europe DNA Methylation Market (by Country), 2019-2030
Figure 12.12: Germany DNA Methylation Market, 2019-2030
Figure 12.13: U.K. DNA Methylation Market, 2019-2030
Figure 12.14: France DNA Methylation Market, 2019-2030
Figure 12.15: Italy DNA Methylation Market, 2019-2030
Figure 12.16: Spain DNA Methylation Market, 2019-2030
Figure 12.17: Rest-of-Europe DNA Methylation Market, 2019-2030
Figure 12.18: Europe DNA Methylation Market (by Translational Research), 2019-2030
Figure 12.19: Asia-Pacific DNA Methylation Market, 2019-2030
Figure 12.20: APAC: Market Dynamics
Figure 12.21: APAC DNA Methylation Market (by Country), 2019-2030
Figure 12.22: China DNA Methylation Market, 2019-2030
Figure 12.23: Japan DNA Methylation Market, 2019-2030
Figure 12.24: India DNA Methylation Market, 2019-2030
Figure 12.25: South Korea DNA Methylation Market, 2019-2030
Figure 12.26: Australia DNA Methylation Market, 2019-2030
Figure 12.27: RoAPAC DNA Methylation Market, 2019-2030
Figure 12.28: Asia-Pacific DNA Methylation Market (by Translational Research), 2019-2030
Figure 12.29: Latin America DNA Methylation Market, 2019-2030
Figure 12.30: Latin America: Market Dynamics
Figure 12.31: Latin America DNA Methylation Market (by Country), 2019-2030
Figure 12.32: Brazil DNA Methylation Market, 2019-2030
Figure 12.33: Mexico DNA Methylation Market, 2019-2030
Figure 12.34: Rest-of-Latin America DNA Methylation Market, 2019-2030
Figure 12.35: Latin America DNA Methylation Market (by Translational Research), 2019-2030
Figure 12.36: RoW DNA Methylation Market, 2019-2030
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Abcam plc: Product Portfolio
Figure 13.3: Abcam plc: Overall Financials, 2016-2018
Figure 13.4: Abcam plc: Revenue (by Region), 2016-2018
Figure 13.5: Abcam plc: R&D Expenditure, 2016-2018
Figure 13.6: Abcam plc: SWOT Analysis
Figure 13.7: Active Motif, Inc.: Product Portfolio
Figure 13.8: Active Motif, Inc.: SWOT Analysis
Figure 13.9: Agilent Technologies, Inc.: Product Portfolio
Figure 13.10: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 13.11: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 13.12: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 13.13: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 13.14: Agilent Technologies, Inc.: SWOT Analysis
Figure 13.15: Bio-Rad Laboratories, Inc.: Portfolio
Figure 13.16: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 13.17: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 13.18: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 13.19: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 13.20: Bio-Rad Laboratories
Figure 13.21: Diagenode Diagnostics S.A.: Product Portfolio
Figure 13.22: Diagenode Diagnostics S.A.: SWOT Analysis
Figure 13.23: EpiGentek Group Inc.: Product Portfolio
Figure 13.24: EpiGentek Group Inc.: SWOT Analysis
Figure 13.25: Exact Sciences Corporation: Portfolio
Figure 13.26: Exact Sciences Corporation: Overall Financials, 2017-2019
Figure 13.27: Exact Sciences Corporation: Revenue (by Segment), 2017-2019
Figure 13.28: Exact Sciences Corporation: Revenue (by Region), 2017-2019
Figure 13.29: Exact Sciences Corporation: R&D Expenditure, 2017-2019
Figure 13.30: Exact Sciences Corporation
Figure 13.33: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 13.34: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 13.35: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.36: F. Hoffmann-La Roche: SWOT Analysis
Figure 13.37: Illumina, Inc.: Product Portfolio
Figure 13.38: Illumina, Inc.: Overall Financials, 2017-2019
Figure 13.39: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 13.40: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 13.41: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 13.42: Illumina, Inc.: SWOT Analysis
Figure 13.43: Merck KGaA: Overall Product Portfolio
Figure 13.44: Merck KGaA: Overall Financials, 2017-2019
Figure 13.45: Merck KGaA: Revenue (by Segment), 2017-2019
Figure 13.46: Merck KGaA: Revenue (by Region), 2017-2019
Figure 13.47: Merck KGaA: Life Science Segment Revenue (by Region), 2017-2019
Figure 13.48: Merck KGaA: R&D Expenditure, 2016-2018
Figure 13.49: Merck KGaA: SWOT Analysis
Figure 13.50: New England Biolabs, Inc.: Product Portfolio
Figure 13.51: New England Biolabs, Inc.: SWOT Analysis
Figure 13.52: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 13.53: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 13.54: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
Figure 13.55: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 13.56: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 13.57: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 13.58: PerkinElmer, Inc.: Portfolio
Figure 13.59: PerkinElmer, Inc.: Overall Financials, 2017-2019
Figure 13.60: PerkinElmer, Inc.: Revenue (by Segment), 2017-2019
Figure 13.61: PerkinElmer, Inc.: Revenue (by Region), 2017-2019
Figure 13.62: PerkinElmer, Inc.: R&D Expenditure, 2017-2019
Figure 13.63: PerkinElmer, Inc.: SWOT Analysis
Figure 13.64: QIAGEN N.V.: Portfolio
Figure 13.65: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 13.66: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 13.67: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 13.68: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 13.69: QIAGEN N.V.: SWOT Analysis
Figure 13.70: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 13.71: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 13.72: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 13.73: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 13.74: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 13.75: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 13.76: Zymo Research Corporation: Product Portfolio
Figure 13.77: Zymo Research Corporation: SWOT Analysis
